← Eichor
Study identifier: NCT06398977 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

Condition: Peritoneal Dialysis Complication · Renal Function Aggravated · Sodium-glucose Co-transporter-2 Inhibitors  ·  Sponsor: Sichuan Academy of Medical Sciences

PhaseNA
Planned participants70
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.

This description comes directly from the study's public registry record.

Talk to the study team

Jin Chen, MD  ·  0086-28-87393195  ·  jessicakxcj@uestc.edu.cn

Xinyi Tan, Master  ·  0086-28-87398195

Always discuss trial participation with your own doctor first.

Locations (1)

Sichuan Academy of Medical Sciences and Sichuan Provincial People's HospitaChengdu, Sichuan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06398977